Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial

Blood (2012) 120 (21): 229.

https://doi.org/10.1182/blood.V120.21.229.229

Published: 2012

Journal Articles

Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)

Stefani Parmentier, MD, Michael Kramer, Katharina Koch, Brigitte Mohr, PhD, Christian Klesse, Christian Thiede, Christoph Röllig, Mathias Hänel, MD, Norbert Schmitz, MD, Kerstin Schäfer-Eckart, Walter E. Aulitzky, Wolfgang E. Berdel, MD, Hubert Serve, Prof. Dr. med., Stefan W. Krause, Jiri Mayer, MD, Martin Bornhäuser, MD, Gerhard Ehninger, Markus Schaich, MD

Blood (2012) 120 (21): 1481.

https://doi.org/10.1182/blood.V120.21.1481.1481

Published: 2012

Journal Articles

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Blood (2012) 120 (21): 144.

https://doi.org/10.1182/blood.V120.21.144.144

Published: 2012

Journal Articles

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Jan Moritz Middeke, MD, Stefani Parmentier, MD, Nael Alakel, MD, Markus Schaich, MD, Christian Thiede, Uwe Platzbecker, MD, Christoph Röllig, Mathias Hänel, MD, Gernot Stuhler, MD, Anke Morgner, MD, Uta Eulenstein, Gerhard Ehninger, Martin Bornhäuser, MD, Johannes Schetelig, MD

Blood (2012) 120 (21): 2017.

https://doi.org/10.1182/blood.V120.21.2017.2017

Published: 2012

Journal Articles

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Sebastian Tuve, MD, Felix Bahr, Rebekka Wehner, PhD, Uwe Platzbecker, MD, Martin Wermke, MD, Nona Shayegi, MD, Jan Moritz Middeke, MD, Christoph Röllig, Johannes Schetelig, Gerhard Ehninger, Marc Schmitz, MD, Martin Bornhäuser, MD

Blood (2012) 120 (21): 4167.

https://doi.org/10.1182/blood.V120.21.4167.4167

Published: 2012

Journal Articles

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Uwe Platzbecker, MD, Friederike Braulke, Andrea Kuendgen, Katharina S. Götze, Gesine Bug, Katayoon Shirneshan, Christoph Röllig, Martin Bornhäuser, MD, Ralph Naumann, MD, Jürgen Neesen, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, Gerhard Ehninger, Prof., Ulrich Germing, MD, Detlef Haase, Martin Wermke, MD

Blood (2012) 120 (21): 921.

https://doi.org/10.1182/blood.V120.21.921.921

Published: 2012

Journal Articles

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Blood (2011) 118 (21): 255.

https://doi.org/10.1182/blood.V118.21.255.255

Published: 2011

Journal Articles

RAD (Lenalidomide, Adriamycin and Dexamethasone) Is a Novel and Very Effective Induction Regimen in Newly Diagnosed Multiple Myeloma Preceding a Risk-Adjusted Transplant Strategy,

Stefan Knop, MD, Christian Langer, MD, Monika Engelhardt, MD, Lars O Muegge, MD, Christoph Röllig, Albrecht Reichle, MD, Martin Gramatzki, Wolf Rösler, MD, Hannes Wandt, MD, Bernd Hertenstein, MD, Susanne Höppner, MD, Helmut Ostermann, MD, Isrid Sturm, MD, Tobias Dechow, MD, Mark Ringhoffer, MD, Marianne Sauerwein, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2011) 118 (21): 3967.

https://doi.org/10.1182/blood.V118.21.3967.3967

Published: 2011

Journal Articles

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,

Uwe Platzbecker, MD, Christina Ganster, Jürgen Neesen, Andrea Kuendgen, MD, Katharina Götze, Gesine Bug, Katayoon Shirneshan, Friederike Braulke, Christoph Röllig, MD, Ralph Naumann, MD, Eckhard Büssemaker, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, MD, Ulrich Germing, MD, Detlef Haase, Gerhard Ehninger, MD

Blood (2011) 118 (21): 3799.

https://doi.org/10.1182/blood.V118.21.3799.3799

Published: 2011

Journal Articles

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

Uwe Platzbecker, MD, Ulrich Schuler, Martin Bornhäuser, Michael Kramer, Markus Schaich, MD, Uta Oelschlagel, Brigitte Mohr, Mathias Hänel, Hannes Wandt, Thomas Wagner, Hermann Einsele, Stefan W. Krause, MD, Heinrich Bodenstein, Walter E. Aulitzky, Norbert Schmitz, Anthony D. Ho, Gerhard Ehninger, MD, Christoph Röllig, MD

Blood (2011) 118 (21): 765.

https://doi.org/10.1182/blood.V118.21.765.765

Published: 2011

Journal Articles

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

Friedrich Stöolzel, MD, Thomas Illmer, MD, Claudia Dill, Michael Kramer, Brigitte Mohr, Christian Thiede, MD, Uwe Platzbecker, MD, Johannes Schetelig, MD, Christoph Röllig, MD, Martin Bornhäuser, Gerhard Ehninger, MD, Markus Schaich, MD

Blood (2011) 118 (21): 935.

https://doi.org/10.1182/blood.V118.21.935.935

Published: 2011

Journal Articles

A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial

Blood (2011) 118 (21): 497.

https://doi.org/10.1182/blood.V118.21.497.497

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Blood (2011) 118 (21): 493.

https://doi.org/10.1182/blood.V118.21.493.493

Published: 2011

Journal Articles

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Christian Thiede, MD, Nona Shayegi, MD, Michael Kramer, Martin Bornhäuser, MD, Markus Schaich, MD, Johannes Schetelig, MD, Uwe Platzbecker, MD, Christoph Röllig, MD, Gerhard Ehninger, MD

Blood (2011) 118 (21): 1445.

https://doi.org/10.1182/blood.V118.21.1445.1445

Published: 2011

Journal Articles

Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial

Friedrich Stölzel, MD, Christoph Röllig, Michael Kramer, Brigitte Mohr, Uta Oelschlägel, Jörgen Radke, Christian Thiede, Martin Bornhaeuser, MD, Gerhard Ehninger, MD, Markus Schaich, MD

Blood (2010) 116 (21): 2154.

https://doi.org/10.1182/blood.V116.21.2154.2154

Published: 2010

Journal Articles

PET-CT Scan for Detection of Extramedullary Acute Myeloid Leukemia

Friedrich Stölzel, MD, Klaus Zoephel, Christoph Röllig, Jörgen Radke, Johannes Schetelig, Uwe Platzbecker, Martin Bornhaeuser, MD, Gerhard Ehninger, MD, Jörg Kotzerke, Markus Schaich, MD

Blood (2010) 116 (21): 2156.

https://doi.org/10.1182/blood.V116.21.2156.2156

Published: 2010

Journal Articles

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Stefan Knop, MD, Christian Langer, MD, Monika Engelhardt, MD, Lars O Muegge, MD, Albrecht Reichle, MD, Christoph Röllig, MD, Martin Gramatzki, MD, Wolf Roesler, MD, Max S Topp, MD, Carmen Wesemeier, MD, Bernd Hertenstein, MD, Isrid Sturm, MD, Tobias Dechow, MD, Martin Kortüm, MD, Marianne Sauerwein, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2010) 116 (21): 1945.

https://doi.org/10.1182/blood.V116.21.1945.1945

Published: 2010

Journal Articles

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Utz O Krug, MD, Anja Koschmieder, Joachim Gerss, PhD, Hubert Serve, MD, Björn Steffen, MD, Gesine Bug, MD, Markus Schaich, MD, Christian Brandts, MD, Christoph Röllig, MD, Gerhard Ehninger, MD, Ulrich Duehrsen, MD, Richard Noppeney, MD, Wolfgang E. Berdel, MD, Steffen Koschmieder, MD, Carsten Müller-Tidow, MD

Blood (2010) 116 (21): 2180.

https://doi.org/10.1182/blood.V116.21.2180.2180

Published: 2010

Journal Articles

Prevalence and Prognostic Impact of RUNX1 Mutations In Patients with Acute Myeloid Leukemia (AML): A Study In 1649 Patients Registered In the AML96 Protocol of the DSIL/SAL

Katharina Gerstenberger, Christoph Röllig, Markus Schaich, Thomas Illmer, Uwe Platzbecker, Martin Bornhäuser, Gerhard Ehninger, Christian Thiede

Blood (2010) 116 (21): 754.

https://doi.org/10.1182/blood.V116.21.754.754

Published: 2010

Journal Articles

Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial

Uwe Platzbecker, Martin Wermke, Jörgen Radke, Alexander Kiani, Franzi Seltmann, Christoph Röllig, Malte von Bonin, Brigitte Mohr, Uta Oelschlägel, Johannes Schetelig, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede

Blood (2010) 116 (21): 679.

https://doi.org/10.1182/blood.V116.21.679.679

Published: 2010

NARROW

Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial

Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

RAD (Lenalidomide, Adriamycin and Dexamethasone) Is a Novel and Very Effective Induction Regimen in Newly Diagnosed Multiple Myeloma Preceding a Risk-Adjusted Transplant Strategy,

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial

PET-CT Scan for Detection of Extramedullary Acute Myeloid Leukemia

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Prevalence and Prognostic Impact of RUNX1 Mutations In Patients with Acute Myeloid Leukemia (AML): A Study In 1649 Patients Registered In the AML96 Protocol of the DSIL/SAL

Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only